Key result
ARBs show early promise in reducing postoperative stiffness and secondary interventions after orthopaedic surgery.
Why the study?
While ARBs combat fibrosis in preclinical settings, literature on their antifibrotic properties in orthopaedics remains scarce despite fibrosis contributing significantly to post-operative stiffness and negative outcomes.
Do Angiotensin II receptor blockers (ARBs) prevent postoperative fibrosis and reduce the need for secondary interventions for stiffness in patients undergoing orthopaedic surgery?
Do Angiotensin II receptor blockers (ARBs) prevent postoperative fibrosis and reduce the need for secondary interventions for stiffness in patients undergoing orthopaedic surgery?
ARBs, traditionally used for cardiovascular conditions, exhibit promising anti-fibrotic properties that may reduce the incidence of debilitating post-operative joint stiffness and the need for subsequent surgical interventions in orthopaedic patients.
ARBs may reduce postoperative stiffness after orthopaedic procedures; leaves open confirmation in prospective randomized trials.
Angiotensin II receptor blockers (ARBs) are commonly prescribed for hypertension and heart failure, and have well-described antifibrotic properties throughout medical literature. The etiology and pathogenesis of fibrosis is biologically complex with a multitude of factors playing a role in the process. Consequently, pathologic fibrosis may be significant within orthopaedics contributing to post-operative stiffness and, ultimately, negative patient outcomes. The pharmacology of ARBs has been described to combat fibrosis in preclinical settings, while the literature of ARBs antifibrotic properties in relation to orthopaedics remains scarce. However, fibrosis is one of the primary factors contributing to tissue healing and functional recovery in the field of orthopaedic surgery. Fibrosis has specifically been described in relation to shoulder surgery, knee arthroplasty and hip arthroscopy. As such, outcomes of various orthopaedic surgeries are dependent upon a balance between tissue healing and stiffness, both of which may be mediated by a fibrotic response. Importantly, ARBs have recently emerged as a potential therapy to combat fibrosis-mediated stiffness in orthopaedic surgery patients. Thus, the following review article seeks to highlight the basic and clinical science of ARBs with emphasis on their implications and indications for orthopaedic surgery and musculoskeletal medicine.
No takes yet. Share an insight, caveat, or question.
Testa et al. (2024) conducted a review in Orthopaedic fibrosis and stiffness. Angiotensin II receptor blockers (ARBs) was evaluated. Angiotensin II receptor blockers (ARBs) demonstrate preclinical success in preventing fibrosis and early clinical promise in reducing postoperative stiffness and subsequent interventions following orthopaedic surgeries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: